Thursday, October 24, 2013 7:48:30 PM
25. A pharmaceutical composition comprising:
a soluble MANF protein comprising a sequence at least 80% identical to SEQ ID NO: 2 or apomorphine; and
at least one additional agent for treating a pancreatic ß-cell disorder.
26. The composition of claim 25, wherein the at least one additional agent is insulin.
http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2013112602&recNum=120&tab=PCTClaims&maxRec=83222&office=&prevFilter=&sortOption=&queryString=diabetes
Note: I think they may have stumbled on to this testing MANF for PD .. as Apomorphine has been used for Parkinson's L-dopa related...
LOI for L-Dopa? does that have any ties to this???????
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM